Kiora Net Profit Margin from 2010 to 2025

KPRX Stock  USD 3.69  0.10  2.64%   
Kiora Pharmaceuticals Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2025. Net Loss is the percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(771.68)
Current Value
(733.10)
Quarterly Volatility
341.01129968
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Kiora Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kiora Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 84.2 K, Selling General Administrative of 4.8 M or Other Operating Expenses of 10.3 M, as well as many indicators such as Price To Sales Ratio of 16 K, Dividend Yield of 0.0 or PTB Ratio of 0.39. Kiora financial statements analysis is a perfect complement when working with Kiora Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Kiora Pharmaceuticals Correlation against competitors.
For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.

Latest Kiora Pharmaceuticals' Net Profit Margin Growth Pattern

Below is the plot of the Net Profit Margin of Kiora Pharmaceuticals over the last few years. It is the percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue. Kiora Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kiora Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Profit Margin10 Years Trend
Slightly volatile
   Net Profit Margin   
       Timeline  

Kiora Net Profit Margin Regression Statistics

Arithmetic Mean(273.13)
Geometric Mean64.07
Coefficient Of Variation(124.85)
Mean Deviation318.76
Median(19.94)
Standard Deviation341.01
Sample Variance116,289
Range769
R-Value(0.85)
Mean Square Error35,326
R-Squared0.72
Significance0.000036
Slope(60.63)
Total Sum of Squares1.7M

Kiora Net Profit Margin History

2025 -733.1
2024 -771.68
2020 -671.03
2019 -2.64
2018 -6.54
2017 -32.44

About Kiora Pharmaceuticals Financial Statements

Kiora Pharmaceuticals investors use historical fundamental indicators, such as Kiora Pharmaceuticals' Net Profit Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kiora Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss(771.68)(733.10)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.